PL37
PL37 (Debio-0827) is an orally active Enkephalinase dual inhibitor (dual inhibition refers to the simultaneous inhibition of Neutral Endopeptidase and Aminopeptidase N activities). PL37 exerts its anti-hyperalgesic effects by activating μ-opioid receptors (µ-opioid receptors), with an ED50 value of 13.4 mg/kg for analgesic effects in mice. PL37 can be used to study diabetic neuropathic pain.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 935481-06-4
- Fòrmula: C22H34N2O6S3
- Peso molecular:518.71
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
Ver todos los productos específicos de isoformas Opioid Receptor
More
Actividad biológica
Chemical Information
-
No. CAS 935481-06-4
-
Peso molecular 518.71
-
Fòrmula C22H34N2O6S3
-
SMILES
CSCC[C@H](N)CSSC[C@@H](CC1=CC=CC=C1)C(NCC(OC(C)OC(OCC)=O)=O)=O
-
Synonyms
Debio-0827
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
[1]. Menéndez L, et al. Inhibition of osteosarcoma-induced thermal hyperalgesia in mice by the orally active dual enkephalinase inhibitor PL37. Potentiation by gabapentin. Eur J Pharmacol. 2008 Oct 31;596(1-3):50-5. [Content Brief]
[2]. Tesfaye S. PL37: a new hope in the treatment of painful diabetic neuropathy?[J]. Pain Management, 2016, 6(2): 129-132. [Content Brief]
[3]. González-Rodríguez S, et al. Involvement of enkephalins in the inhibition of osteosarcoma-induced thermal hyperalgesia evoked by the blockade of peripheral P2X3 receptors. Neurosci Lett. 2009 Nov 20;465(3):285-9. [Content Brief]
[4]. Descheemaeker A, et al. Dual enkephalinase inhibitor PL37 as a potential novel treatment of migraine: evidence from a rat model. Brain. 2022 Aug 27;145(8):2664-2670. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)